Evicenter
MarkdownMedical informationP&T meetings
QTORIN rapamycin 3.9 percent gel

Microcystic lymphatic malformations

Last updated
76 sources

Section 6 of 6

References

76 sources

  1. Abtahi-Naeini et al. (2025) (opens in a new tab)
  2. Adams et al. (2016) (opens in a new tab)
  3. Allemang-Trivalle et al. (2026) (opens in a new tab)
  4. Badia et al. (2020) (opens in a new tab)
  5. Balakrishnan et al. (2012) (opens in a new tab)
  6. Bonilla-Velez et al. (2025) (opens in a new tab)
  7. Cai et al. (2023) (opens in a new tab)
  8. Çalışkan et al. (2018) (opens in a new tab)
  9. Canaud et al. (2021) (opens in a new tab)
  10. Cheng et al. (2017) (opens in a new tab)
  11. ClinicalTrials.gov NCT05050149 (opens in a new tab)
  12. Cui et al. (2026) (opens in a new tab)
  13. Dodds et al. (2020) (opens in a new tab)
  14. FDA Orphan Drug Designations and Approvals (2021) (opens in a new tab)
  15. Gallagher et al. (2022) (opens in a new tab)
  16. García-Montero et al. (2017) (opens in a new tab)
  17. García-Montero et al. (2019) (opens in a new tab)
  18. Ghaffarpour et al. (2019) (opens in a new tab)
  19. Ghaffarpour et al. (2022) (opens in a new tab)
  20. Goldenberg et al. (2025) (opens in a new tab)
  21. Gu and Sebaratnam (2024) (opens in a new tab)
  22. Hollman et al. (2026) (opens in a new tab)
  23. Huerta et al. (2024) (opens in a new tab)
  24. ICH GCP NCT06239480 (opens in a new tab)
  25. Ivars and Redondo (2017) (opens in a new tab)
  26. Jinnin et al. (2025) (opens in a new tab)
  27. Kalwani and Rockson (2021) (opens in a new tab)
  28. Kamireddy et al. (2026) (opens in a new tab)
  29. Kinoshita et al. (2026) (opens in a new tab)
  30. Kirkham et al. (2015) (opens in a new tab)
  31. Kitchloo et al. (2024) (opens in a new tab)
  32. Lapa and Sandre (2026) (opens in a new tab)
  33. Le Sage et al. (2018) (opens in a new tab)
  34. Leboulanger et al. (2023) (opens in a new tab)
  35. Leducq et al. (2019) (opens in a new tab)
  36. Mäkinen et al. (2021) (opens in a new tab)
  37. Marchand et al. (2022) (opens in a new tab)
  38. Maruani et al. (2021) (opens in a new tab)
  39. Palvella Therapeutics Breakthrough Therapy designation announcement (2023) (opens in a new tab)
  40. Palvella Therapeutics corporate presentation (2026) (opens in a new tab)
  41. Palvella Therapeutics corporate update and 2026 outlook announcement (2026) (opens in a new tab)
  42. Palvella Therapeutics expanded access policy (opens in a new tab)
  43. Palvella Therapeutics first NDA module submission announcement (2026) (opens in a new tab)
  44. Palvella Therapeutics first quarter 2026 results announcement (2026) (opens in a new tab)
  45. Palvella Therapeutics Form 10-K (2025) (opens in a new tab)
  46. Palvella Therapeutics Form 10-K (2026) (opens in a new tab)
  47. Palvella Therapeutics Form 10-Q (2026) (opens in a new tab)
  48. Palvella Therapeutics full-year 2025 results announcement (2026) (opens in a new tab)
  49. Palvella Therapeutics investor relations website (opens in a new tab)
  50. Palvella Therapeutics NDA acceptance and Priority Review announcement (2026) (opens in a new tab)
  51. Palvella Therapeutics NDA submission completion announcement (2026) (opens in a new tab)
  52. Palvella Therapeutics phase 2 publication announcement (2025) (opens in a new tab)
  53. Palvella Therapeutics phase 2 topline results announcement (2023) (opens in a new tab)
  54. Palvella Therapeutics pipeline update announcement (2023) (opens in a new tab)
  55. Palvella Therapeutics pipeline web page (opens in a new tab)
  56. Palvella Therapeutics presentation (2026) (opens in a new tab)
  57. Palvella Therapeutics rolling review announcement (2026) (opens in a new tab)
  58. Palvella Therapeutics second quarter 2026 results announcement (2026) (opens in a new tab)
  59. Palvella Therapeutics SELVA and TOIVA data announcement (2026) (opens in a new tab)
  60. Palvella Therapeutics SELVA topline results announcement (2026) (opens in a new tab)
  61. Palvella Therapeutics website (opens in a new tab)
  62. Palvella Therapeutics World Congress of Pediatric Dermatology announcement (2025) (opens in a new tab)
  63. PeDRA (2024) (opens in a new tab)
  64. Saibene et al. (2023) (opens in a new tab)
  65. Seront et al. (2023) (opens in a new tab)
  66. Seront et al. (2026) (opens in a new tab)
  67. Teng et al. (2023) (opens in a new tab)
  68. Teng et al. (2024) (opens in a new tab)
  69. Teng et al. (2025) (opens in a new tab)
  70. Treat (2026) (opens in a new tab)
  71. Treat et al. (2024) (opens in a new tab)
  72. Vandersteen et al. (2025) (opens in a new tab)
  73. Wiegand et al. (2009) (opens in a new tab)
  74. Xu et al. (2026) (opens in a new tab)
  75. Yonekura et al. (2022) (opens in a new tab)
  76. Zenner et al. (2019) (opens in a new tab)